China Meheco Group (600056.SH) subsidiary's mupirocin API approved for marketing

date
16:04 20/11/2026
avatar
GMT Eight
China Meheco Group (600056.SH) announced that recently, Tianfang Pharmaceutical Co., Ltd. ("Tianfang Pharmaceutical"), a wholly-owned subsidiary of the company, received the "Chemical API Marketing Application Approval Notice" for mupirocin issued by the National Medical Products Administration. The drug is mainly used for skin and soft tissue infections caused by Gram-positive cocci, such as primary infections including impetigo, furuncles, and folliculitis, as well as secondary infections of skin conditions such as eczema, dermatitis, ulcers, and trauma.
China Meheco Group (600056.SH) announced that recently, Tianfang Pharmaceutical Co., Ltd. ("Tianfang Pharmaceutical"), a wholly-owned subsidiary of the company, received the "Chemical API Marketing Application Approval Notice" for mupirocin issued by the National Medical Products Administration. The drug is mainly used for skin and soft tissue infections caused by Gram-positive cocci, such as primary infections including impetigo, furuncles, and folliculitis, as well as secondary infections of skin conditions such as eczema, dermatitis, ulcers, and trauma.